Abstract:Background: The recent regulatory approvals of immune checkpoint protein inhibitors, such as ipilimumab, pembrolizumab, nivolumab, atezolizumab, durvalumab, and avelumab ushered a new era in cancer therapy. These inhibitors do not attack tumor cells directly but instead mobilize the immune system to re-recognize and eradicate tumors, which endows them with unique advantages including durable clinical responses and substantial clinical benefits. PD-1/PD-L1 inhibitors, a pillar of immune checkpoint protein inhibitors, have demonstrated unprecedented clinical efficacy in more than 20 cancer types. Besides monoclonal antibodies, diverse PD1/PD-L1 inhibiting candidates, such as peptides, small molecules have formed a powerful collection of weapons to fight cancer. Methods: The goal of this review is to summarize and discuss the current PD-1/PD-L1 inhibitors including candidates under clinical development, their molecular interactions with PD-1 or PD-L1, the disclosed structure-activity relationships of peptides and small molecules as inhibitors. Results: Current PD-1/PD-L1 inhibitors under clinical development are exclusively dominated by antibodies. The molecular interactions of therapeutic antibodies with PD-1 or PD-L1 have been gradually elucidated for the design of novel inhibitors. Various peptides and traditional small molecules have been investigated in preclinical model to discover novel PD-1/PD-L1 inhibitors. Conclusion: Peptides and small molecules may play an important role in immuno-oncology because they may bind to multiple immune checkpoint proteins via rational design, opening opportunity for a new generation of novel PD-1/PD-L1 inhibitors.

Regulation of post-translational modification of PD-L1 and associated opportunities for novel small-molecule therapeutics

Posttranslational regulatory mechanism of PD-L1 in cancers and associated opportunities for novel small-molecule therapeutics

The Nuclear Transportation of PD-L1 and the Function in Tumor Immunity and Progression

Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics

[Regulation of PD-L1 posttranslational modification and its application progress in tumor immunotherapy]

Emerging therapeutic frontiers in cancer: insights into posttranslational modifications of PD-1/PD-L1 and regulatory pathways

Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway

Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion

Post-translational Modification of PD-1: Potential Pathways for Cancer Immunotherapy

Post-translational Modification of PD-1: Potential Targets for Cancer Immunotherapy

Small Molecules As PD-1/PD-L1 Pathway Modulators for Cancer Immunotherapy

Anti-Tumor Potential of Post-Translational Modifications of PD-1

Post-translational regulations of PD-L1 and PD-1: Mechanisms and opportunities for combined immunotherapy

Recent Findings in the Posttranslational Modifications of PD-L1

PD-1/PD-L1 Inhibitors for Immuno-oncology: from Antibodies to Small Molecules

Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy

Recent advance of peptide-based molecules and nonpeptidic small-molecules modulating PD-1/PD-L1 protein-protein interaction or targeting PD-L1 protein degradation

Posttranslational Modifications in PD-L1 Turnover and Function: From Cradle to Grave

Regulation of PD-L1 expression in the tumor microenvironment

From Monoclonal Antibodies to Small Molecules: the Development of Inhibitors Targeting the Pd-1/Pd-L1 Pathway

Emerging Role of Ubiquitination/deubiquitination Modification of PD-1/PD-L1 in Cancer Immunotherapy